Education
About Us
Working with TipRanks
Follow Us
Milestone Pharmaceuticals (MIST)
NASDAQ:MIST
MIST Stock Chart & Stats
$1.71
-$0.02(-0.90%)
At close: 4:00 PM EST
$1.71
-$0.02(-0.90%)
Day’s Range― - ―
52-Week Range$0.63 - $3.06
Previous CloseN/A
Volume143.50K
Average Volume (3M)1.81M
Market Cap
$145.64M
Enterprise Value$156.16M
Total Cash (Recent Filing)$82.58M
Total Debt (Recent Filing)$57.21M
Price to Earnings (P/E)―
Beta2.17
Next Earnings
Mar 31, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding85,169,340
10 Day Avg. Volume1,332,046
30 Day Avg. Volume1,808,590
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)11.17
Price to Sales (P/S)0.00
P/FCF Ratio-5.08
Enterprise Value/Market Cap1.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-263.79
Enterprise Value/Ebitda-2.91
Forecast
1Y Price Target
$8.00Price Target Upside367.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$37.94M
Bulls Say, Bears Say
Bulls Say
Commercial Funding And Launch ReadinessThe company’s funds from royalty financing and an equity raise provide capital to execute detailed launch plans for Cardamyst in PSVT, reducing near‑term financing risk for commercialization.
European Regulatory ProgressEuropean Medicines Agency acceptance of the marketing application advances the nasal spray toward potential EU approval, creating a path to new market access and partnership opportunities.
First‑in‑class Outpatient TherapyPotential approval would position Cardamyst as the first rapid, reliable outpatient treatment for paroxysmal supraventricular tachycardia, addressing an underserved patient population and enabling prescriptions outside healthcare settings.
Bears Say
Commercial Execution RiskChallenges in physician adoption, patient access, and distribution for an outpatient nasal product could slow market uptake and undercut sales forecasts during the launch phase.
Intellectual Property And Funding UncertaintyIntellectual property uncertainty coupled with the potential need for additional funding if revenues fall short could pressure valuation and the company’s ability to advance pipeline programs.
Regulatory Risk For Label ExpansionRegulatory hurdles for pursuing additional indications such as atrial fibrillation could delay or prevent expansion of the program, limiting potential future revenue streams.
Milestone Pharmaceuticals News
MIST FAQ
What was Milestone Pharmaceuticals’s price range in the past 12 months?
Milestone Pharmaceuticals lowest stock price was $0.63 and its highest was $3.06 in the past 12 months.
What is Milestone Pharmaceuticals’s market cap?
Milestone Pharmaceuticals’s market cap is $145.64M.
When is Milestone Pharmaceuticals’s upcoming earnings report date?
Milestone Pharmaceuticals’s upcoming earnings report date is Mar 31, 2026 which is in 29 days.
How were Milestone Pharmaceuticals’s earnings last quarter?
Milestone Pharmaceuticals released its earnings results on Nov 12, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.164 by $0.044.
Is Milestone Pharmaceuticals overvalued?
According to Wall Street analysts Milestone Pharmaceuticals’s price is currently Undervalued.
Does Milestone Pharmaceuticals pay dividends?
Milestone Pharmaceuticals does not currently pay dividends.
What is Milestone Pharmaceuticals’s EPS estimate?
Milestone Pharmaceuticals’s EPS estimate is -0.16.
How many shares outstanding does Milestone Pharmaceuticals have?
Milestone Pharmaceuticals has 85,169,340 shares outstanding.
What happened to Milestone Pharmaceuticals’s price movement after its last earnings report?
Milestone Pharmaceuticals reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.164. Following the earnings report the stock price went up 1.047%.
Which hedge fund is a major shareholder of Milestone Pharmaceuticals?
Currently, no hedge funds are holding shares in MIST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Milestone Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (367.84% Upside)
$8.00 (367.84% Upside)
Blogger Sentiment
Bullish
MIST Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 7.3%
Last 30 Days ▼ 7.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.72%
12-Months-Change
Fundamentals
Return on Equity
-260.65%
Trailing 12-Months
Asset Growth
6.10%
Trailing 12-Months
Company Description
Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
MIST Stock 12 Month Forecast
Average Price Target
$8.00
▲(367.84% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Seres Therapeutics
―
Avalo Therapeutics
―
Elicio Therapeutics
―
Alto Neuroscience, Inc.
―
Ownership Overview
1.36% Insiders
0.09% Mutual Funds
7.87% Other Institutional Investors
88.86% Public Companies and
Individual Investors